Outcome of the Board Meeting is enclosed herewith.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Supriya Lifescience reported strong FY26 results with revenue from operations growing 18.9% year-on-year to Rs. 8,278.75 million from Rs. 6,964.85 million in FY25. Net profit after tax improved 11.3% to Rs. 2,091.20 million from Rs. 1,879.58 million. The Board recommended a final dividend of Rs. 1 per equity share (50% on face value of Rs. 2 each), subject to shareholder approval at the AGM. Q4 standalone revenue surged 50.2% to Rs. 2,765.28 million versus Rs. 1,841.09 million in Q4 FY25. The statutory auditors issued an unmodified opinion on the financial results, confirming clean reporting without qualifications. The meeting was held on May 27, 2026 from 3:45 PM to 6:00 PM.
The double-digit growth in revenue and profitability, combined with a maiden dividend recommendation and clean audit opinion, signals strong operational performance and may attract positive investor sentiment. The 50% dividend payout also demonstrates management confidence in cash generation.